Physician profile
Carlos Baleeiro
NPI 1841223039
$264,676.97
in general payments reported to CMS, 2019-2025
26 companies · $5,306 in 2025
The $5,306 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $22K · 2021: $58K · 2022: $18K · 2023: $75K · 2024: $66K · 2025: $5,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139K · Travel and Lodging: $4,377 · Food and Beverage: $3,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $139,000.00 |
| Travel and Lodging | $4,376.80 |
| Food and Beverage | $3,523.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $155,181.45 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $79,607.36 | 2019-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28,752.13 | 2019-2024 | Ofev |
| Olympus America INC. | $203.59 | 2019-2022 | |
| Allergan, INC. | $130.46 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Portola Pharmaceuticals, LLC | $103.84 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $77.51 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $70.98 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $54.60 | 2019 | |
| Pfizer INC. | $44.08 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $36.50 | 2019 | |
| Insmed, INC. | $33.91 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $28.71 | 2020 | |
| Vantive US Healthcare LLC | $27.19 | 2025 | Renal - Acute |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.92 | 2022 | |
| Viatris Specialty LLC | $23.28 | 2025 | Yupelri |
| United Therapeutics Corporation | $22.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.75 | 2022 | |
| Advanced Respiratory, INC | $18.24 | 2021 | |
| Philips North America LLC | $17.57 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.90 | 2021 | |
| Boston Scientific Corporation | $15.95 | 2019 | |
| Genentech USA, INC. | $14.25 | 2019 | |
| Merck Sharp & Dohme LLC | $14.17 | 2024 | Recarbrio, Zerbaxa, Dificid |
| Grifols USA, LLC | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Baleeiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.